Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Autor:	Wöll E; St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria e.woell@krankenhaus-zams.at., Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria., Keil F; 3rd Medical Department, Hanusch Hospital, Vienna, Austria., Gruenberger B; St. John of God's Hospital, Vienna, Austria., Hejna M; Medical University of Vienna, Vienna, Austria., Eisterer W; Medical University Hospital Innsbruck, Innsbruck, Austria., Fridrik MA; Kepler Universitätsklinikum GmbH, Med Campus III, Klinik für Interne, Linz, Austria., Ulmer H; Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria., Trommet V; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria., Huemer F; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria., Weiss L; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria., Greil R; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2017 Oct; Vol. 37 (10), pp. 5553-5558.
DOI:	10.21873/anticanres.11987
Abstrakt:	Background/aim: Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acquired chemotherapy resistance. Patients and Methods: Sequential chemotherapy (oxaliplatin and irinotecan followed by docetaxel) combined with bevacizumab was investigated in the GASTRIC-3 trial. Patients achieving at least stable disease were continued on maintenance bevacizumab. Results: Objective response rate was available in 33 patients: Complete response (CR) 12.1%, partial response (PR) 39.4%, stable disease (SD) 27.3%. Median time to progression was 7.0 months (95%CI=5.0-11.0) and median overall survival was 11 months (95%CI=9.0-15.0). Of note, two patients continue to receive bevacizumab maintenance therapy for more than 5 years with ongoing CR. Conclusion: Combining sequential chemotherapy with oxaliplatin/irinotecan and docetaxel with bevacizumab followed by bevacizumab maintenance is feasible and clinically active in advanced gastric cancer. (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu